-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationAspirin
On December 15, 2021, Eastern Time, the FDA approved AbbVie's Rinvoq for the treatment of psoriatic arthritis, and also approved Pfizer's Xeljanz for the treatment of active ankylosing spondylitis
The delayed approval of the application for the treatment of inflammatory diseases occurred after the FDA completed the safety risk review and labeling restrictions of oral JAK inhibitor drugs
The limitations of these labels are not surprising
The extra caution for JAK inhibitor drugs stems from a post-marketing study by Xeljanz
The approval of Rinvoq's new psoriatic arthritis is based on two phase III trials
Psoriatic arthritis and ankylosing spondylitis are relatively minor indications for JAK drugs
In contrast, atopic dermatitis is a major indication observed by industry analysts
For rheumatoid arthritis and psoriatic arthritis, Rinvoq is only used in a dose of 15 mg
But Porges is not sure whether AbbVie can obtain approval for the high-dose Rinvoq for the treatment of eczema
Reference source: AbbVie's Rinvoq, Pfizer's Xeljanz win new uses after extended reviews as JAK safety woes linger